Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 9:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 5,769 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Positron Emission Tomography, Tazemetostat
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, lenalidomide, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more
Conditions
Multiple Myeloma
Interventions
Descartes-11, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Madison, Wisconsin
Conditions
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
Interventions
Tinostamustine
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • New York, New York + 1 more
Conditions
Non-Hodgkin Lymphoma
Interventions
IGN002
Biological
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Santa Monica, California • Pittsburgh, Pennsylvania
Active, not recruiting Phase 3 Interventional Results available

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
PF-06801591, Bacillus Calmette-Guerin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
44
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 24 more
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Terminated Not applicable Interventional Results available

In-Vivo Activated T-Cell Depletion to Prevent GVHD

NCT00594308
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Lymphoma, Non-Hodgkin's, Mantle-Cell Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis
Interventions
Cyclophosphamide, Fludarabine, Cyclosporine, Mycophenolate mofetil, Basiliximab
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Multiple Myeloma
Interventions
Isatuximab, Carfilzomib, Dexamethasone
Biological · Drug
Lead sponsor
Thomas Martin, MD
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more
Conditions
Adrenocortical Carcinoma
Interventions
IL-13-PE
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Valproic acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Rhabdomyosarcoma
Interventions
Vinorelbine, Mocetinostat
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
Interventions
Cobimetinib
Drug
Lead sponsor
Carl Allen
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 9 more
Conditions
Neoplasms
Interventions
carboplatin + irinotecan, irinotecan
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Terminated Phase 1Phase 2 Interventional Results available

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NCT03901573
Conditions
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions
NT-I7, atezolizumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Follicular Lymphoma
Interventions
Loncastuximab tesirine, Rituximab
Drug
Lead sponsor
Juan P. Alderuccio, MD
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
5
States / cities
Fort Myers, Florida • Miami, Florida • Ann Arbor, Michigan + 2 more
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
arsenic trioxide, tretinoin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
15 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Acute Lymphoblastic Leukemia, Leukemia
Interventions
Ponatinib, Venetoclax, Mini-hyper CVD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colon Cancer, Rectal Cancer, Liver Metastases
Interventions
Tas-102, SIR-Sphere
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Conditions
Neoplasm Malignant
Interventions
SAR566658
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Cincinnati, Ohio • San Antonio, Texas
Conditions
Lung Cancer
Interventions
karenitecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
44
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 28 more
Conditions
Neoplasm
Interventions
Liposome Entrapped Paclitaxel Easy to Use
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
Tampa, Florida • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Conditions
Hormone Refractory Prostate Cancer
Interventions
ADENOVIRUS/PSA VACCINE
Biological
Lead sponsor
David M Lubaroff
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin